Biologics have revolutionized the treatment and prevention of many disabling and life-threatening diseases. However, biologics are contributing to the rising costs of healthcare, and this may restrict access to these important medicines.
A biosimilar is an approved biologic with comparable quality, safety and efficacy to an approved reference product or brand.
Biosimilars help more patients experience the life-enhancing benefits of biologic treatment.
Sandoz, the pioneer and global leader in biosimilars
Sandoz is committed to increasing patient access to high-quality, life-enhancing biosimilars. It is the pioneer and global leader in biosimilars, with three marketed products: Binocrit®, Omnitrope® (the first biosimilar in Europe), and Zarzio®/Zarxio® (the very first biosimilar to be approved in the US).
With a leading pipeline, Sandoz plans to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020. This will be enabled by 11 filings over a three-year period (2015-2017), with the company having already submitted six and received one approval. Sandoz’ early-stage pipeline has additional assets in oncology as well as other specialty therapeutic areas with plans to start new programs every year.
As a division of the Novartis Group, Sandoz is well-positioned to lead the biosimilars industry based on its experience and capabilities in development, manufacturing and commercialization.